Literature DB >> 35991731

Extranodal natural killer/T-cell lymphoma nasal type.

Benjamin S Daines1, Rahul M Varman1, Tam Q Nguyen1.   

Abstract

Extranodal natural killer/T-cell lymphoma nasal type (ENKL) is a rare neoplasm uncommon in the US. Diagnosis is complicated by low incidence and rapid tissue necrosis preventing timely histologic confirmation. We report the case of a 55-year-old woman with ENKL who faced a challenging diagnostic workup due to widespread nasal tissue necrosis and nonspecific sinus-related complaints. While ENKL is significantly more common in Asia and South America, clinicians worldwide should maintain a high level of suspicion for patients presenting with nonspecific nasopharyngeal complaints who have signs of tissue necrosis. Early recognition and treatment with combined radiotherapy and chemotherapy can improve survival.
Copyright © 2022 Baylor University Medical Center.

Entities:  

Keywords:  Extranodal NK-T-cell lymphoma nasal type; nasal obstruction; non-Hodgkin lymphoma; sinusitis

Year:  2022        PMID: 35991731      PMCID: PMC9373771          DOI: 10.1080/08998280.2022.2071074

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN: 0899-8280


  20 in total

Review 1.  T/NK cell non-Hodgkin's lymphoma of the sinonasal tract.

Authors:  P Sheahan; M Donnelly; S O'Reilly; M Murphy
Journal:  J Laryngol Otol       Date:  2001-12       Impact factor: 1.469

2.  A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis.

Authors:  Seok Jin Kim; Dok Hyun Yoon; Arnaud Jaccard; Wee Joo Chng; Soon Thye Lim; Huangming Hong; Yong Park; Kian Meng Chang; Yoshinobu Maeda; Fumihiro Ishida; Dong-Yeop Shin; Jin Seok Kim; Seong Hyun Jeong; Deok-Hwan Yang; Jae-Cheol Jo; Gyeong-Won Lee; Chul Won Choi; Won-Sik Lee; Tsai-Yun Chen; Kiyeun Kim; Sin-Ho Jung; Tohru Murayama; Yasuhiro Oki; Ranjana Advani; Francesco d'Amore; Norbert Schmitz; Cheolwon Suh; Ritsuro Suzuki; Yok Lam Kwong; Tong-Yu Lin; Won Seog Kim
Journal:  Lancet Oncol       Date:  2016-02-10       Impact factor: 41.316

Review 3.  How I treat NK/T-cell lymphomas.

Authors:  Eric Tse; Yok-Lam Kwong
Journal:  Blood       Date:  2013-05-07       Impact factor: 22.113

4.  Management of NK/T-Cell Lymphoma, Nasal Type.

Authors:  Pamela B Allen; Mary Jo Lechowicz
Journal:  J Oncol Pract       Date:  2019-10       Impact factor: 3.840

5.  PD1 blockade with pembrolizumab is highly effective in relapsed or refractory NK/T-cell lymphoma failing l-asparaginase.

Authors:  Yok-Lam Kwong; Thomas S Y Chan; Daryl Tan; Seok Jin Kim; Li-Mei Poon; Benjamin Mow; Pek-Lan Khong; Florence Loong; Rex Au-Yeung; Jabed Iqbal; Colin Phipps; Eric Tse
Journal:  Blood       Date:  2017-02-10       Impact factor: 22.113

6.  Extranodal NK/T-cell lymphoma, nasal type (angiocentric T-cell lymphoma): A review about the terminology.

Authors:  Rashmi S Metgud; Jitendra J Doshi; Sarang Gaurkhede; Ravindra Dongre; Ravindra Karle
Journal:  J Oral Maxillofac Pathol       Date:  2011-01

Review 7.  Prognostic significance of Epstein-Barr virus DNA in NK/T-cell lymphoma: a meta-analysis.

Authors:  Qian Fei; Xiao-Kang Tian; Jing Wu; Hong-Ming Zhu; Yan Wang; Fan-Yu Peng; Wen-Jun Zhang; Li Yin; Xia He
Journal:  Onco Targets Ther       Date:  2018-02-26       Impact factor: 4.147

Review 8.  Epstein-Barr Virus-Positive Natural Killer/T-Cell Lymphoma.

Authors:  Qingqing Cai; Jun Cai; Yu Fang; Ken H Young
Journal:  Front Oncol       Date:  2019-05-14       Impact factor: 6.244

9.  A case report of an extranodal NK/T-cell lymphoma nasal type, occurring primarily in eyes with masquerade syndrome.

Authors:  Feng Zhang; Xuanchu Duan; Ke Liu
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.817

Review 10.  Nasal NK/T cell lymphoma presents with long-term nasal blockage and fever: a rare case report and literature review.

Authors:  Hai Zou; Ke-Hua Pan; Liang Wu; Hong-Ying Pan; Ya-Hui Ding; Ming-Hua Zheng
Journal:  Oncotarget       Date:  2016-02-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.